Advertisement

Topics

Companies Related to "A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection" [Most Relevant Company Matches] RSS

14:20 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection" found in our extensive corporate database of over 50,000 company records.

Showing "Study Japan Safety Antiviral Activity With Chronic Hepatitis" Companies 1–25 of 3,500+

Extremely Relevant

Eiger BioPharmaceuticals, Inc.

Eiger is focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infections. Eiger's pipeline includes repurposed clinical stage therapeutic agents as well as preclinical NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger investors include InterWest Partners www.interwest...


Relevant

Achillion Pharmaceuticals

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HBV and HCV), HIV and herpes viruses.Product Candidate PortfolioThe Company’s broad drug developm...

World of Health Biotech Co.Ltd

Anti HBV Specific Active Immunotherapy (Anti HBV Therapeutic Vaccine) using recombinant hepatitis B vaccine (standard HBV vaccine) as an immunogenic specific antigen and several cytokines as an immune adjuvant is a new antiviral approach for chronic HBV infection. The first and most critical setp in the design of an anti HBV therapeutic vaccine is the selection of the specific antigens that will b...


SciClone Pharmaceuticals

SciClone is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases, such as hepatitis B, hepatitis C, cancer, immune system disorders and cystic fibrosis.

Novirio Pharmaceutical Incorporated

Novirio Pharmaceuticals is an independent biopharmaceutical company engaged in the discovery and development of pharmaceuticals for the treatment of life threatening human viral diseases. Building on our expertise in nucleoside chemistry and biology and other small molecule therapeutic compounds, we are positioned to become a leader in the antiviral pharmaceuticals market. Our efforts focus on sig...

ViroDefense INC

ViroDefense Inc is an antiviral research, development and consulting company that advocates for and facilitates development of effective antiviral pharmaceuticals that address global public health threats. ViroDefense Inc is presently focused on development of antiviral drugs for poliomyelitis. Currently, there are no poliovirus antiviral drug products available. ViroDefense INC has offices in...

Debiopharm Group

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect on HCV replication both in vitro and in vivo. Debio 025 has excellent antiviral activity against a broad range of genotypes (1, 2, 3 and 4); a high barrier to the development of resistance; and the pos...

Hepatitis B Foundation

The Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide through research, education and patient advocacy. Visit www.hepb.org.

REPLICor Inc

REPLICor Inc. is a biopharmaceutical company developing novel broad-spectrum antiviral drugs. Its lead compound, REP 9, is active against 12 viral families including influenza, hepatitis B and C, HIV, RSV and herpes. The company’s business strategy is to enter into an alliance with a major pharmaceutical company to further develop and market its technology.

World Hepatitis Alliance

The following people have provided quotes expressing their support to the World Hepatitis Alliance campaign for a WHO resolution on viral hepatitis. For further information please contact worldhepday@fleishman.com

International Society for the Study of Xenobiotics

Man's use of xenobiotics dates from antiquity but interest in foreign compound metabolism dates from only the mid-19th century when the knowledge and techniques of organic chemistry were first applied to its study. For nearly a century thereafter biotransformation was generally equated with "detoxication" or the elimination of a compound's biological activity.This view changed in the late 1930s wi...

CMI - Centers for Medical Innovation AG

CMI AG is a bioscience company that is engaged in the identification, development and commercialization of a new generation of plant derived prescription drugs for the treatment of serious chronic diseases such as chronic hepatitis B and C, Parkinsons Disease. CMI AG first began operations in Ocotber 1997 and has currently two plant products in development. Exclusive Options on two more promising ...

Viridae Clinical Sciences Incorporated

Viridae Clinical Sciences is an antiviral research and testing, specializing in herpes and hepatitis. Viridae consists of a full-service Contract Research Organization (CRO), a fully accredited virology laboratory and a clinic that serves as an investigator site for virology based clinical trials.

IATEC

Since its foundation, IATEC has focused on delivering high-quality antiviral research across the globe. Clinical trials are becoming increasingly complex; we understand the scientific challenges to be faced during these times, but we also see these challenges as opportunities.To serve our mission even better, IATEC has divided its activities between the IATEC Foundation, IATEC Clinical Trial Servi...

Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. Novelos is seeking to build a pipeline through licensing or acquiring clinical stage compounds or technologies for oncology indications. Our lead compound, NOV-002, has been administered to approximately ...

Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions. The Company's most popular product is its Xin-Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to...

&intoconnection

&intoconnection performed a study on what it means for people to be strongly or weakly connected. Due to the international nature of the study, it is not only possible to measure connection by country, but it is also possible to compare connection between countries. The 14 countries studied were China, Japan, the U.S., Russia, Germany, Great Britain, France, Spain, South Africa, Argentina, Isr...

RiboTargets

RiboTargets is a privately owned pharmaceutical company that specialises in anti-infective research and development. Its therapeutic interests include antibacterial and antiviral agents (including HIV and Hepatitis C). The company has developed a unique computational screening platform technology RiboDock® which supports the rapid and effective generation of lead compounds from target structures....

iQur Ltd

iQur® is a specialty pharmaceutical company at the forefront of international breakthroughs in the detection, treatment and monitoring of Hepatitis C and other liver diseases.iQur exists to provide clinicians with a comprehensive, 24–48 hour service for genotyping, qualitation and quantification of both the Hepatitis C (HCV) and Hepatitis B (HBV) viruses.Founded in 2003 by liver disease special...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

S.T.Japan-USA, LLC

S.T. Japan USA, LLC is the American branch of S.T. Japan, Inc. . It is a member of the S.T. Japan Group. Our main functions and activities are:To directly sell to End-Users located in the USA and the other Americas, products developed and produced by S.T. Japan, Inc. and other Japanese manufacturers represented by S.T.Japan, Inc. .Our Key Products are: - Spectra Databases - Spectroscopic Accessor...

Dynavax Technologies

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulat...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Triangle Pharmaceuticals Incorporated

Triangle Pharmaceuticals develop new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus ("HBV"). Triangle Pharmaceuticals have an existing portfolio of six licensed drug candidates and one drug candidate for which they have an option to acquire a license. Five of these drug candidates are currently under active d...

Intarcia Therapeutics, Inc

Intarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. Our highly experienced team uses its expertise in clinical medicine, pharmaceutical development and regulatory affairs to identify and develop new uses or alternative formulat...


More From BioPortfolio on "A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks